The latest version of the national medical insurance catalog has recently been released. In order to further promote the development of breast cancer prevention and treatment, let the whole society care about women's health and pay attention to cancer prevention and treatment, recently, the Guangdong Health Science Popularization Trip "Jointly Enter the Era of breast cancer Chronic Disease Management" activity was successfully held. The activity was carried out in the way of "online+offline". On the one hand, many medical experts carried out breast cancer science popularization through the network platform, and on the other hand, the event sponsor and media reporters went to the front lines of major hospitals in Guangdong Province to carry out in-depth dialogues on breast cancer prevention and treatment, the efficacy of "subcutaneous preparations", health care under the new medical insurance catalog and other topics. Medical experts from Guangzhou, Yangjiang, Zhongshan, Heyuan, Shantou, Chaozhou, Jieyang and other places participated in this science popularization activity, including well-known breast health experts in Guangdong Province. Interview experts: Li Jie and Gong Chang. Expert: Li Jie, Discipline Leader of the Thyroid and Breast Disease Diagnosis and Treatment Center of Guangzhou Women and Children's Center, Department Director, Doctoral Director, Chief Physician, Postdoctoral Collaborating Mentor: Expert: Gong Chang, Professor/Chief Physician of Breast Surgery, Yixian Breast Cancer Hospital, Sun Yat sen Memorial Hospital, Sun Yat sen University, Professor/Chief Physician, Doctoral Supervisor of Surgery (I) - Entering the New Catalogue of Medical Insurance - "Subcutaneous Preparation" of Trastuzumab On December 13, 2023, the National Medical Insurance Administration announced the adjustment results of the 2023 National Medical Insurance Catalogue, with a total of 126 new drugs added to the National Medical Insurance Drug Catalogue, including 21 types of cancer drugs. In particular, the "subcutaneous preparation" of trastuzumab for breast cancer treatment was included in the list of new medical insurance, and was officially implemented on January 1, 2024. It is reported that trastuzumab is a HER2 targeted drug originally developed by Roche for the treatment of breast cancer and has been on the market for 20 years. Among breast cancer patients, HER2 positive breast cancer patients account for about 25%. This subtype has high malignancy and poor prognosis. At present, the "Toto double target regimen" of trastuzumab combined with Partouzumab has become the standard regimen for the treatment of HER2 positive breast cancer, and is in an unshakable position in the anti HER2 treatment. Subcutaneous preparations bring new development opportunities to public hospitals, which can further improve the turnover rate of daytime wards and hospitalizations, and effectively improve the utilization of medical resources. According to clinical statistics, the subcutaneous preparation of trastuzumab can save 81% of the single nursing time of medical staff and reduce 83% of the single visit time of patients. Professor Li Jie stated that due to the convenience of subcutaneous injection, the use of trastuzumab as a "subcutaneous preparation" can not only save patients' time, but also reduce human and material investment for medical staff, which is conducive to the efficient and reasonable allocation of medical resources; For nursing staff, it can greatly reduce nursing workload and improve bed utilization rate; In the pharmaceutical department, more time can be spent on other drug research to improve work efficiency and better meet the needs of high-quality development. Professor Gong Chang believes that the inclusion of "subcutaneous preparations" of trastuzumab in the new medical insurance directory will change the medical diagnosis and treatment mode and safety management mode